Tags

Type your tag names separated by a space and hit enter

Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis.

Abstract

The red wine polyphenol, resveratrol, is highly effective in treating type 2 diabetes mellitus (T2DM) in animal models, but there is no consensus regarding its efficacy in humans. We conducted a systematic review, which included searches in nine scholarly databases and six clinical trial registries, and identified randomized controlled clinical trials whereby resveratrol was used as an adjunct to pharmaceutical interventions in T2DM. Meta-analysis on clinical parameters was performed for available data. Of 764 articles originally identified, data from six unique datasets, examining a total of 196 T2DM patients (104 resveratrol, 92 control/placebo) ultimately met inclusion criteria. Statistically significant (p < 0.05) positive effects, indicating that resveratrol supplementation was more effective than placebo/control, were identified for systolic blood pressure, hemoglobin A1c, and creatinine, but not for fasting glucose, homeostatic model assessment of insulin resistance, diastolic blood pressure, insulin, triglycerides, LDL, or HDL cholesterol. No major adverse events were reported and side effects of resveratrol were not different than placebo/control. Though limitations in sample size and treatment duration preclude definitive changes in clinical practice, significant improvements in multiple cardiometabolic biomarkers and an excellent safety profile support resveratrol as a leading candidate as an adjunct to pharmacological management of T2DM.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Jacksonville University College of Health Sciences, Jacksonville, FL, USA.

    ,

    Source

    Molecular nutrition & food research 59:1 2015 Jan pg 147-59

    MeSH

    Blood Pressure
    Cholesterol, HDL
    Cholesterol, LDL
    Creatinine
    Databases, Factual
    Diabetes Mellitus, Type 2
    Dietary Supplements
    Glycated Hemoglobin A
    Humans
    Insulin
    Randomized Controlled Trials as Topic
    Resveratrol
    Stilbenes
    Triglycerides

    Pub Type(s)

    Journal Article
    Meta-Analysis
    Review
    Systematic Review

    Language

    eng

    PubMed ID

    25138371

    Citation

    Hausenblas, Heather A., et al. "Resveratrol Treatment as an Adjunct to Pharmacological Management in Type 2 Diabetes Mellitus--systematic Review and Meta-analysis." Molecular Nutrition & Food Research, vol. 59, no. 1, 2015, pp. 147-59.
    Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis. Mol Nutr Food Res. 2015;59(1):147-59.
    Hausenblas, H. A., Schoulda, J. A., & Smoliga, J. M. (2015). Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis. Molecular Nutrition & Food Research, 59(1), pp. 147-59. doi:10.1002/mnfr.201400173.
    Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol Treatment as an Adjunct to Pharmacological Management in Type 2 Diabetes Mellitus--systematic Review and Meta-analysis. Mol Nutr Food Res. 2015;59(1):147-59. PubMed PMID: 25138371.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis. AU - Hausenblas,Heather A, AU - Schoulda,Jennifer A, AU - Smoliga,James M, Y1 - 2014/10/09/ PY - 2014/03/10/received PY - 2014/07/21/revised PY - 2014/07/29/accepted PY - 2014/8/21/entrez PY - 2014/8/21/pubmed PY - 2015/9/26/medline KW - Cardiometabolic KW - French paradox KW - Nutraceutical KW - SIRT1 KW - Sirtuin SP - 147 EP - 59 JF - Molecular nutrition & food research JO - Mol Nutr Food Res VL - 59 IS - 1 N2 - The red wine polyphenol, resveratrol, is highly effective in treating type 2 diabetes mellitus (T2DM) in animal models, but there is no consensus regarding its efficacy in humans. We conducted a systematic review, which included searches in nine scholarly databases and six clinical trial registries, and identified randomized controlled clinical trials whereby resveratrol was used as an adjunct to pharmaceutical interventions in T2DM. Meta-analysis on clinical parameters was performed for available data. Of 764 articles originally identified, data from six unique datasets, examining a total of 196 T2DM patients (104 resveratrol, 92 control/placebo) ultimately met inclusion criteria. Statistically significant (p < 0.05) positive effects, indicating that resveratrol supplementation was more effective than placebo/control, were identified for systolic blood pressure, hemoglobin A1c, and creatinine, but not for fasting glucose, homeostatic model assessment of insulin resistance, diastolic blood pressure, insulin, triglycerides, LDL, or HDL cholesterol. No major adverse events were reported and side effects of resveratrol were not different than placebo/control. Though limitations in sample size and treatment duration preclude definitive changes in clinical practice, significant improvements in multiple cardiometabolic biomarkers and an excellent safety profile support resveratrol as a leading candidate as an adjunct to pharmacological management of T2DM. SN - 1613-4133 UR - https://www.unboundmedicine.com/medline/citation/25138371/full_citation L2 - https://doi.org/10.1002/mnfr.201400173 DB - PRIME DP - Unbound Medicine ER -